Terns Pharmaceuticals (TERN) 10-Q2022 Q1 Quarterly report

Filed: 16 May 22, 4:43pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Additionally, administered, adult, agent, agonism, allosteric, arrangement, ASC, AST, behalf, billion, biologic, biopsy, BMI, body, bone, borrowing, brain, broader, California, cancer, care, CML, complex, comprised, concurrent, convenient, criteria, eligible, emptying, endpoint, equivalent, exceed, explore, factorial, feature, fee, figure, Food, Foster, frequent, gastric, GGT, glucagon, gut, illustrated, implicated, implicit, inclusion, incremental, index, inhibition, insulin, kinase, lead, length, leukemia, marrow, maximum, mg, molecular, msec, multicenter, myeloid, myristoyl, national, noncancellable, noncirrhotic, optimized, package, partner, pattern, payroll, PDFF, peptide, pipeline, pocket, pool, poor, potent, practical, prioritization, prioritized, proceeding, proprietary, QSAR, randomized, readily, regimen, region, relaxation, relevant, Rent, rental, reset, ROU, RSU, satiety, schedule, secretion, semaglutide, sense, shelf, short, space, spend, structure, suitable, suppression, titration, TKI, tumor, tyrosine, underway, unmet, week, Wegovy, widespread

Removed: absorb, acquiring, advanced, allocation, anniversary, annually, applied, arrived, beneficiary, Centre, close, complementary, compounded, conclusion, controlling, deconsolidated, deconsolidation, deposit, discovery, entity, estimation, exercising, expectation, expiration, fact, factor, gain, hepatic, hierarchy, histological, inflation, involvement, irrevocable, line, Lirui, Litai, multiplied, order, ownership, parent, Partnership, percentage, power, prospectively, PWERM, reconciliation, redeemable, remeasured, resource, retained, round, scenario, secured, selective, shown, subsidiary, sum, termination, treated, unilateral, variable, VIE

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TERN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Terns Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 16, 2022	By:	/s/ Senthil Sundaram
		Senthil Sundaram
		Chief Executive Officer (Principal Executive Officer)